Abteilung für Immundermatologie und experimentelle Allergologie, Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover.
Universitätsklinik für Dermatologie und Venerologie, Medizinische Universität Graz, Austria.
J Dtsch Dermatol Ges. 2021 Jan;19(1):151-168. doi: 10.1111/ddg.14371.
This guideline is an update from August 2020 the S2k-guideline "Atopic dermatitis" published in 2015. The reason for updating this chapter of the guideline were the current developments in the field of systemic therapy of atopic dermatitis. The agreed recommendations for systemic treatment in atopic dermatitis of the present guideline are based on current scientific data. Due to the approval of dupilumab for the treatment of moderate to severe atopic dermatitis, which cannot be treated sufficiently with topical drugs alone, this part of the guideline has now been adapted and newly consented. The indication for systemic therapy and the therapeutic response to topical and systemic treatment should be recorded and documented in a suitable form in clinic and practice. A standardized documentation of the indication for system therapy in atopic dermatitis can be recommended and is also part of the updated chapter of this guideline.
本指南是对 2015 年发布的 S2k 指南“特应性皮炎”的更新。更新本指南这一章的原因是特应性皮炎系统治疗领域的当前发展。本指南中关于特应性皮炎系统治疗的共识建议是基于当前的科学数据。由于批准度普利尤单抗用于治疗不能单独通过局部药物充分治疗的中重度特应性皮炎，因此本指南的这一部分现已进行了调整和新的协商。系统治疗的适应证以及对局部和系统治疗的治疗反应应在临床和实践中以合适的形式进行记录和记录。可以推荐对特应性皮炎的系统治疗适应证进行标准化记录，这也是本指南更新章节的一部分。
